Citations

Clear

1315 citation(s) found for "Kyle, RA".

Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
Drosou, Maria Eleni , Vaughan, Lisa E. , Muchtar, Eli , Dingli, David , Fonder, Amie , Gertz, Morie A. , Gonsalves, Wilson I. , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Kyle, Robert A. , Lacy, Martha Q. , Lin, Yi , Lopez, Camden , Lust, John A., Russell, Stephen J. , Sidana, Surbhi , Siddiqui, Mustaqeem , Warsame, Rahma , Dispenzieri, Angela , Fonder, Amie L, Gertz, Morie A , Gonsalves, Wilson , Hwa, Yi L , Kourelis, Taxiarchis , Lopez, Camden L, Rajkumar, S Vincent , Sidana, Surbhi , Sidiqi, M Hasib , Warsame, Rahma , Leung, Nelson , Muchtar, E , Russell, Stephen J , Siddiqui, Mustaqeem A , Lopez, Camden L , Dingli, David , Lin, Yi , Buadi, Francis K. , Dispenzieri, Angela , Go, Ronald S. , Rajkumar, S. Vincent , Sidiqi, M Hasib , Leung, Nelson

Mayo Clinic

American Journal of Hematology | January 15, 2021 | Volume: 96 | Issue: 4 | Pages: 446-454

10.1002/ajh.26092 | PMID 33428787 Get It

AbstractThree sets of criteria (International Society of Amyloidosis [ISA], Palladini and Kastritis) were independently developed for staging, progression and response criteria to predict renal survival in patients with AL amyloidosis. We evaluated these criteria using a cohort of 495 newly diagnosed AL amyloidosis patients with renal involvement using time to event competing risk analysis at baseline, 3, 6 and 12 months after treatment. Only Palladini and Kastritis had a staging system and both predicted a higher risk of end stage renal disease (ESRD) in the stage III vs stage I patients but only the Palladini model was predictive for stage II patients. At 3 months, risk of ESRD was significantly higher for Palladini and ISA renal progression (hazard ratio [HR] 2.8 [95% CI: 1.5–5.3, p = .001] and 2.5 [CI: 1.4–4.6, p = .004, respectively]), but renal response was not significantly protective; conversely, the risk of ESRD was not significantly higher for the Kastritis renal progression, but was significantly protective for the Kastritis renal responders (HR 0.38 [95% CI: 0.17–0.84], p = .017). Both progression and response with ISA, Palladini and Kastritis criteria were predictive of ESRD at 6 months and 12 months. While the Palladini staging criteria at baseline, and the ISA and Palladini criteria for progression at 3 months performed better than the Kastritis criteria at baseline and 3 months post‐treatment, the Kastritis criteria performed better for response 3 months after treatment. All three sets of criteria performed well at and after 6 months post‐treatment. These differences are important when choosing endpoints for clinical trials.
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Gajjar, Amar , Robinson, Giles , Smith, Kyle , Lin, Tong , Merchant, Thomas E. , Chintagumpala, Murali , Mahajan, Anita , Su, Jack , Bouffet, Éric , Bartels, Ute , Schechter, Tal , Robertson, Thomas , Nicholls, Wayne , Gururangan, Sridharan , Schroeder, Kristin , Sullivan, Michael , Wheeler, Greg, Hansford, Jordan R. , Kellie, Stewart J., McCowage, Geoffrey , Fisher, Michael J. , Krasin, Matthew J. , Stewart, Clinton F. , Buchhalter, Ivo , Tatevossian, Ruth , Orr, Brent A. , Neale, Geoffrey , Klimo, Paul , Boop, Frederick A. , Pfister, Stefan M. , Gilbertson, Richard J. , Onar‐Thomas, Arzu , Ellison, David W. , Robinson, Giles W , Hassall, Tim , Gururangan, Sridharan , Schroeder, Kristin , Sullivan, Michael , Hansford, Jordan R , Krasin, Matthew J , Buchhalter, Ivo , Tatevossian, Ruth G , Orr, Brent A , Neale, Geoff , Pfister, Stefan M , Northcott, Paul A , Merchant, Thomas E , Bouffet, Eric , Bartels, Ute , Cohn, Richard Jules , Broniscer, Alberto , Srinivasan, Ashok

Mayo Clinic

Journal of Clinical Oncology | January 6, 2021 | Volume: 39 | Issue: 7 | Pages: 822-835

10.1200/jco.20.01372 | PMID 33405951 Get It

PURPOSE SJMB03 (ClinicalTrials.gov identifier: NCT00085202 ) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. PATIENTS AND METHODS Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were molecularly classified into subgroups (Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4) and subtypes based on DNA methylation profiles and overlaid with gene mutations from next-generation sequencing. Coprimary study end points were (1) to assess the relationship between ERBB2 protein expression in tumors and progression-free survival (PFS), and (2) to estimate the frequency of mutations associated with WNT and SHH tumors. Clinical and molecular risk factors were evaluated, and the most robust were used to model new risk-classification categories. RESULTS Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year PFS was 83.2% (95% CI, 78.4 to 88.2) for average-risk patients (n = 227) and 58.7% (95% CI, 49.8 to 69.1) for high-risk patients (n = 103). No association was found between ERBB2 status and PFS in the overall cohort ( P = .74) or when patients were stratified by clinical risk ( P = .71). Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors and PTCH1 (38%), TP53 (21%), and DDX3X (19%) in SHH tumors. Methylome profiling classified 53 WNT (17.4%), 48 SHH (15.7%), 65 group 3 (21.3%), and 139 group 4 (45.6%) tumors. A comprehensive clinicomolecular risk factor analysis identified three low-risk groups (WNT, low-risk SHH, and low-risk combined groups 3 and 4) with excellent (5-year PFS > 90%) and two very high-risk groups (high-risk SHH and high-risk combined groups 3 and 4) with poor survival (5-year PFS < 60%). CONCLUSION These results establish a new risk stratification for future medulloblastoma trials.
Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents
Miller, Matthew A. , Molina, Kyle C. , Gutman, Jonathan A. , Scherger, Sias , Lum, Jessica , Mossad, Sherif B. , Burgess, Mary Jo , Chuang, Sally T, Jacobs, Samantha E, Melendez, Dante P. , Shah, Dimpy P. , Zimmer, Andrea , Syed, Sadia, Walker, Randall C., Poeschla, Eric M. , Abidi, Maheen Z. , Abidi, Maheen Z , Abidi, Maheen Z , Burgess, Mary, Cheng, Matthew Pellan , Jacobs, Samantha E, Sohail, M. Rizwan , Syed, Sadia

Mayo Clinic

Open Forum Infectious Diseases | December 30, 2020 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/ofid/ofaa646 | PMID 33575424 Get It

Abstract Background The survival benefit of combination antifungal therapy for invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined. Methods This multicenter, retrospective study included HM and HCT recipients with proven or probable IM between January 1, 2007 and December 31, 2017 from 10 transplant centers across North America. Results Sixty-four patients with proven (n = 47) or probable (n = 17) IM defined by 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) consensus definitions were included. Thirty-nine (61%) were HCT recipients (95% allogeneic). Sites of infection included rhino-orbital-cerebral (33), pulmonary (30%), disseminated (19%), gastrointestinal (3%), and cutaneous (3%). Surgical debridement was performed in 66%. Initial antifungal treatment consisted of the following: lipid formulation of amphotericin B (AmB) alone (44%), AmB + posaconazole (25%), AmB + echinocandin (13%), AmB + isavuconazole (8%), posaconazole alone (5%), and isavuconazole alone (3%). All-cause mortality at 30 days and 1 year were 38% and 66%, respectively. Initial treatment with AmB plus posaconazole or isavuconazole (n = 28) was associated with a trend toward lower treatment failure compared with AmB (n = 21) (42% vs 64%, P = .136). Conclusions Long-term survival with IM among HM and HCT populations remains poor. However, initial use of AmB + azole in conjunction with surgery may result in less treatment failure. More evidence from prospective controlled studies is needed to confirm this observation.
Mortality and Glycemic Control Among Patients With Diabetes Mellitus and Uterine Or Ovarian Cancer
Kusne, Yael , Kosiorek, Heidi , Buras, Matthew , Coppola, Kyle , Verona, Patricia M , Cook, Curtiss B. , Karlin, Nina J. , Kusne, Yael N , Kosiorek, Heidi E , Buras, Matthew R , Coppola, Kyle E , Cook, Curtiss B

Mayo Clinic

Future Science OA | December 18, 2020 | Volume: 7 | Issue: 3 | Pages: No page available

10.2144/fsoa-2020-0158 | PMID 33552546 Get It

Technical Note: kV‐independent coronary calcium scoring: A phantom evaluation of score accuracy and potential radiation dose reduction
Tao, Shengzhen , Sheedy, Emily N., Bruesewitz, Michael R. , Weber, Nikkole M. , Williams, Kyle , Halaweish, Ahmed F., Schmidt, Bernhard , Williamson, Eric E. , McCollough, C, Sheedy, Emily, Bruesewitz, Michael, Weber, Nikkole, McCollough, Cynthia, Leng, Shuai

Mayo Clinic

Medical Physics | December 18, 2020 | Volume: 48 | Issue: 3 | Pages: 1307-1314

10.1002/mp.14663 | PMID 33332626 Get It

Purpose To determine the accuracy of CT number and calcium score of a kV‐independent technique based on an artificial 120 kV reconstruction, and its potential to reduce radiation dose. Methods Anthropomorphic chest phantoms were scanned on a third‐generation dual‐source CT system equipped with the artificial 120 kV reconstruction. First, a phantom module containing a 20‐mm diameter hydroxyapatite (HA) insert was scanned inside the chest phantoms at different tube potentials (70–140 kV) to evaluate calcium CT number accuracy. Next, three small HA inserts (diameter/length = 5 mm) were inserted into a pork steak and scanned inside the phantoms to evaluate calcium score accuracy at different kVs. Finally, the same setup was scanned using automatic exposure control (AEC) at 120 kV, and then with automatic kV selection (auto‐kV). Phantoms were also scanned at 120 kV using a size‐dependent mA chart. CT numbers of soft tissue and calcium were measured from different kV images. Calcium score of each small HA insert was measured using commercial software. Results The CT number difference from 120 kV was small with tube potentials from 90 to 140 kV for both soft tissue and calcium (maximal difference of 4/5 HU, respectively). Consistent calcium scores were obtained from images of different kVs compared to 120 kV, with a relative difference <8%. Auto‐kV provided a 25–34% dose reduction compared to AEC alone. Conclusion A kV‐independent calcium scoring technique can produce artificial 120 kV images with consistent soft tissue and calcium CT numbers compared to standard 120 kV examinations. When coupled with auto‐kV, this technique can reduce radiation by 25–34% compared to that with AEC alone, while providing consistent calcium scores as that of standard 120 kV examinations.
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma
Cook, Joselle , Johnson, Isla McKerrow , Higgins, Alexandra , Sidana, Surbhi , Warsame, Rahma , Gonsalves, Wilson I. , Gertz, Morie A. , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Johnson, Isla, Gonsalves, Wilson , Lacy, Martha, Dispenzieri, Angela , Kourelis, Taxiarchis , Hwa, Yi L , Leung, Nelson , Rajkumar, S Vincent , Gertz, Morie A , Higgins, Alexandra , Sidana, Surbhi , Dingli, David , Cook, Joselle M , Buadi, Francis K. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | December 17, 2020 | Volume: 96 | Issue: 3 | Pages: 330-337

10.1002/ajh.26074 | PMID 33326116 Get It

AbstractInduction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden for patients and reduce treatment‐emergent neuropathy. This study evaluates the response rates and outcomes with different schedules of bortezomib in VRd administered for first‐line treatment for patients with newly diagnosed MM (NDMM). We retrospectively analyzed patients treated with upfront VRd from June 30th 2008 to December 31st 2018, for variations of bortezomib administration. Five hundred and fifty‐five (555) NDMM patients met inclusion criteria; median age 63 years and 61% men. Bortezomib was administered twice weekly every 21 days in 43%, once weekly every 21 days in 41% and once weekly every 28 days in 16%. Though peripheral sensory neuropathy was more frequent with twice weekly dosing (P = .002), this group achieved shorter time to best response (P = .01). Weekly every 21‐day treatment saw higher VGPR or better rates (P = .02). However, with median follow up time of 37 months (IQR 22–56), we found no difference in PFS or OS among the groups. While small differences in response rates were found among the varying administration schedules of bortezomib administration, there was no significant effect on PFS or OS. Given that VRd remains a first line standard of care option for newly diagnosed MM, in the absence of a large trial comparing bortezomib dosing schedule modifications, these results are helpful in supporting current practices of once weekly administration.
The Military Orthopedics Tracking Injuries and Outcomes Network: A Solution for Improving Musculoskeletal Care in the Military Health System
Mauntel, Timothy C. , Freedman, Brett A. , Provencher, Matthew T. , Tokish, John M. , Lee, Ian E, Bailey, James R. , Burns, Travis C. , Cameron, Kenneth L. , Grenier, Eric, Haley, Chad A., McDonald, Lucas S. , Pallis, Mark, Posner, Matthew, Rivera, Jessica C. , Roach, Christopher J, Robins, Richard J. , Sheean, Andrew J. , Slabaugh, Mark A. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Potter, Benjamin Kyle , Provencher, Matthew T. , Rhon, Daniel I. , LeClere, Lance E. , Owens, Brett D. , Roach, Christopher J, Schmitz, Matthew R.

Mayo Clinic

Military Medicine | December 6, 2020 | Volume: 187 | Issue: 3-4 | Pages: e282-e289

10.1093/milmed/usaa304 | PMID 33242087 Get It

Abstract Introduction Musculoskeletal injuries are an endemic amongst U.S. Military Service Members and significantly strain the Department of Defense’s Military Health System. The Military Health System aims to provide Service Members, military retirees, and their families the right care at the right time. The Military Orthopedics Tracking Injuries and Outcomes Network (MOTION) captures the data that can optimize musculoskeletal care within the Military Health System. This report provides MOTION structural framework and highlights how it can be used to optimize musculoskeletal care. Materials and Methods MOTION established an internet-based data capture system, the MOTION Musculoskeletal Data Portal. All adult Military Health System patients who undergo orthopedic surgery are eligible for entry into the database. All data are collected as routine standard of care, with patients and orthopedic surgeons inputting validated global and condition-specific patient reported outcomes and operative case data, respectively. Patients have the option to consent to allow their standard of care data to be utilized within an institutional review board approved observational research study. MOTION data can be merged with other existing data systems (e.g., electronic medical record) to develop a comprehensive dataset of relevant information. In pursuit of enhancing musculoskeletal injury patient outcomes MOTION aims to: (1) identify factors which predict favorable outcomes; (2) develop models which inform the surgeon and military commanders if patients are behind, on, or ahead of schedule for their targeted return-to-duty/activity; and (3) develop predictive models to better inform patients and surgeons of the likelihood of a positive outcome for various treatment options to enhance patient counseling and expectation management. Results This is a protocol article describing the intent and methodology for MOTION; thus, to date, there are no results to report. Conclusions MOTION was established to capture the data that are necessary to improve military medical readiness and optimize medical resource utilization through the systematic evaluation of short- and long-term musculoskeletal injury patient outcomes. The systematic enhancement of musculoskeletal injury care through data analyses aligns with the National Defense Authorization Act (2017) and Defense Health Agency’s Quadruple Aim, which emphasizes optimizing healthcare delivery and Service Member medical readiness. This transformative approach to musculoskeletal care can be applied across disciplines within the Military Health System.
NCOG-69. SEX DIFFERENCES IN GLIOBLASTOMA PATIENT SURVIVAL AS A FUNCTION OF EXTENT OF SURGICAL RESECTION AND CYCLES OF ADJUVANT TEMOZOLOMIDE DURING STANDARD-OF-CARE REGIMENS
Lorence, Julia, White, Haylye, Rickertsen, Cassandra , Singleton, Kyle , Johnston, Sandra K. , Porter, Alyx B. , Mrugała, Maciej M. , Hu, Leland , Swanson, Kristin R. , Swanson, Kristin R , Bencomo, Tomas , Massey, Susan Christine , Hawkins‐Daarud, Andrea , Bendok, Bernard R. , Rubin, Joshua B

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii144-ii145

10.1093/neuonc/noaa215.607 Get It

Abstract OBJECTIVE Glioblastoma (GBM) is the most common malignant primary brain tumor in adults, with males more commonly affected than females(1.6:1). Despite advancements in treatments, prognosis is dismal with a median overall survival of 15 months. Our aim was to investigate sex as a variable in GBM patient survival after receiving incremental levels of standard-of-care treatment regimens – different extents of surgical resection and different numbers of cycles of adjuvant temozolomide chemotherapy. METHODS Drawing from our extensive multi-institutional brain tumor repository, we investigated GBM subjects with overall survival (OS), extent of resection (EOR), number of temozolomide (TMZ) cycles, and sex data (n=620, males: n=387, females: n=233). Cox proportional hazard ratios were computed to investigate the multivariable predictive value of the patient variables with OS. Patients were then divided into groups based on their sex, EOR (either biopsy, subtotal resection (STR) or gross total resection (GTR)), and TMZ cycles (I: &lt; 6 cycles, II: 7-11 cycles and III: &gt;12 cycles). RESULTS We observed that STR was beneficial for females (HR=0.52; CI=0.33-0.83; p-value=0.013), while for males the benefit was not detected (HR=0.73; CI=0.46-1.15; p-value=0.173) for STR but was detectable for GTR (HR=0.58, CI=0.37-0.90; p-value=0.014). Females receiving 7-11 cycles of TMZ showed a survival benefit (HR=0.52; CI=0.12-0.53; p-value=0.048) while males in the same group did not (HR=0.74; CI=0.46-1.19; p-value=0.21), in comparison to those in group I of TMZ cycles. No sex differences were identified in patients receiving &lt; =6 cycles or &gt;=12 cycles. CONCLUSION Together, our results contribute to the growing literature that sex differences exist in GBM patients, even in response to standard-of-care therapies. This should be accounted for when designing clinical trials for GBM so that we may advance our pursuit to deliver personalized medicine.
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
Chi, Andrew , Kurz, Sylvia C. , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , DeGroot, John, Hall, Matthew D. , Daghistani, Doured , Schwartz, Jonathan , Cartaxo, Rodrigo T. , Siada, Ruby , Miklja, Zachary , Bruzek, Amy K., Wierzbicki, Kyle , Paul, Alyssa , Wolfe, Ian, Leaoard, Marcia, Garton, Hugh , Mody, Rajen , Robertson, Patricia L. , Merdinger, Krystal, Venneti, Sriram , Oster, Wolfgang, Allen, Joshua E. , Kawakibi, Abed Rahman , Tarapore, Rohinton S. , Gardner, Sharon L , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Harrison, Rebecca A , Mehta, Minesh P. , Odia, Yazmín , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Umemura, Yoshie , Yadav, Viveka Nand , Cantor, Evan , Lu, Guangrong , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_3 | Pages: iii347-iii347

10.1093/neuonc/noaa222.305 Get It

Abstract ONC201, a bitopic DRD2 antagonist and allosteric ClpP agonist, has shown encouraging efficacy in H3 K27M-mutant glioma. Given that the thalamus has the highest extra-striatal expression of DRD2, we performed an integrated preclinical and clinical analysis of ONC201 in thalamic H3 K27M-mutant glioma. ONC201 was effective in mouse intra-uterine electroporation (IUE)-generated H3 K27M-mutant gliomas, with an in vitro IC50 of 500 nM and 50% prolongation of median survival in vivo (p=0.02, n=14). We analyzed thalamic H3 K27M-mutant glioma patients treated with ONC201 on active clinical trials as of 5/22/19 enrollment (n=19 recurrent and 10 post-radiation, non-recurrent; 5–70 years old). As of 12/18/2019, PFS6 and OS12 are 26.3% and 36.8%, respectively, in the recurrent group. For non-recurrent patients, with median follow up of 21.9 months (8.6–26.6) from diagnosis, median PFS or OS have not been reached. This surpasses historical OS of 13.5 months. Best response by RANO includes 1 CR, 3 PR, 4 SD, 8 PD for recurrent patients and 2 PR, 4 SD, 1 PD for non-recurrent patients (4 on-trial patients experienced regressions that are yet unconfirmed responses). Median duration of response for recurrent patients is 14.0 months (2.0–33.1). Furthermore, H3 K27M cell-free tumor DNA in plasma and CSF correlated with MRI response. In summary, single agent ONC201 administered at recurrence, or adjuvantly following radiation, demonstrates promising clinical efficacy in thalamic H3 K27M-mutant glioma patients who currently have no effective treatments following radiation. Investigations are ongoing to assess whether micro-environmental DRD2 expression explains the early exceptional responses in thalamic H3 K27M-mutant glioma.
Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients
Bryant, Laura , Li, Dong , Cox, Samuel G., Wilson, Khadija , Janssen, Kevin A. , March, Michael , Sherr, Elliott H. , Fregeau, Brieana, Wierenga, Klaas J. , Wadley, Alexandrea, Mancini, Grazia M.S., Powell‐Hamilton, Nina , Kamp, Jiddeke van de, Grebe, Theresa A., Ross, Alison , Crawford, Heather P., Powis, Zöe , Cho, Megan T. , Willing, Marcia, Schot, Rachel , Afenjar, Alexandra , Lessel, Davor , Wagner, Matias , Klopstock, Thomas , Winkelmann, Juliane , Retterer, Kyle , Schuette, Jane L., Innis, Jeffrey W. , Pizzino, Amy , Lüttgen, Sabine, Denecke, Jonas , Strom, Tim M., Monaghan, Kristin G. , Study, DDD, Yuan, Zuo‐Fei , Dubbs, Holly , Bend, Renee, Lee, Jennifer A. , Lyons, Michael J. , Hoefele, Julia , Günthner, Roman , Keren, Boris , Radtke, Kelly, Sherbini, Omar , Mrokse, Cameron, Helbig, Katherine L. , Odent, Sylvie , Mercier, Sandra , Küry, Sébastien , Redon, Richard , Reinson, Karit , Wojcik, Monica H. , Õunap, Katrin , Ilves, Pilvi , Innes, A. Micheil , Kernohan, Kristin D. , Costain, Gregory , Zackai, Elaine H. , Kitson, Hilary, Study, CAUSES, Martin, Martin G., Martínez-Agosto, Julián A. , Network, Undiagnosed Diseases, Nelson, Stan F., Palmer, Christina G.S. , Papp, Jeanette C. , Parker, Neil H., Wan, Jijun , Yoon, Amanda J., Zheng, Allison, Carli, Diana , Brusco, Alfredo , Tartaglia, Marco , Thomas, Jennifer Muncy, Weiss, Marjan M. , Gotway, Garrett , Stuurman, Kyra E. , Thompson, Michelle L. , Stumpel, Constance T. R. M., Stevens, Servi J.C. , Stegmann, Alexander P.A. , Tveten, Kristian , Vøllo, Arve, Prescott, Trine , Fagerberg, Christina , Laulund, Lone Walentin , Larsen, Martin J. , Byler, Melissa, Lebel, Robert Roger, Dean, Joy, Mercimek‐Andrews, Saadet , Neira, Juanita, Allen, Margot I. Van, Sellars, Elizabeth A. , Louie, Raymond J. , Cathey, Sara , Brokamp, Elly , Héron, Delphine, Snyder, Molly, Simon, Celeste, Cruz, Xavier de la , Padilla, Natàlia , García, Benjamin A. , Håkonarson, Håkon , Bhoj, Elizabeth , Nelson, Stanley F. , Sherr, Elliott , Dean, John , Lessel, Davor , Klopstock, Thomas , Kury, Sebastien , Brusco, Alfredo , McWalter, Kirsty , Stevens, Servi J C , Crump, J Gage , Hakonarson, Hakon , Bhoj, Elizabeth J , Tartaglia, Marco , Li, Dong , Wagner, Matias , Redon, Richard , Õunap, Katrin , de la Cruz, Xavier , Padilla, Natália , March, Michael , Hoefele, Julia , Marchione, Dylan M. , Joiner, Evan F. , Lee, Pearl , Nair, Divya, Kamp, Jiddeke M. van de , Manwaring, Linda P. , Nava, Caroline , Catarino, Claudia B. , Monaghan, Kristin G. , Study, DDD, Reutter, Heiko , Radtke, Kelly , Cogné, Benjamin , Bezieau, Stéphane , Besnard, Thomas , Meyn, M Stephen , Chitayat, David A. , Lehman, Anna , Study, CAUSES, Network, Undiagnosed Diseases, Sinsheimer, Janet S. , Vilain, Eric J. N. , Brimble, Elise , Ferrero, Giovanni Battista , Radio, Francesca Clementina , Barresi, Sabina , Umaña, Luis Alfredo , Hurst, Anna , Vergano, Samantha A. Schrier , Norman, Jennifer, Longo, Nicola , Vanderver, Adeline , Chung, Wendy K.

Mayo Clinic

Science Advances | December 3, 2020 | Volume: 6 | Issue: 49 | Pages: No page available

10.1126/sciadv.abc9207 | PMID 33268356 Get It

Germ line mutations in H3F3A and H3F3B cause a previously unidentified neurodevelopmental syndrome.